Mumbai, April 15, 2025: Dr. Lal PathLabs Limited (“DLPL” / “Dr. Lal PathLabs”), a leader in diagnostic healthcare, has introduced Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry – a breakthrough test for accurately identifying different types of Amyloid proteins. With this launch, DLPL becomes the first diagnostic chain in South Asia to offer this highly specialized test.
Key Highlights:
· First-of-its-kind in South Asia – DLPL pioneers this advanced diagnostic solution.
· Nationwide Availability – Samples can be collected from anywhere in India and sent to National Reference Lab, Rohini, New Delhi for testing.
· Accurate Diagnosis – Helps doctors determine the specific type of Amyloid, enabling targeted treatment and better outcomes.
· Access for Hospitals – All hospitals can facilitate sample collection for patients and send to Dr Lal PathLabs for testing.
Commenting on the launch, Mr. Shankha Banerjee, CEO of Dr. Lal PathLabs, said, “Our mission is to bring world-class diagnostics to India. By introducing this advanced Amyloidosis test, we aim to provide doctors with critical insights for accurate diagnosis and personalized treatment. We are proud to be the first diagnostic chain in South Asia to offer this cutting-edge solution.”
Adding further, Dr. Alok Sharma, R&D Head & Director Renal Pathology & Electron Microscopy, stated, “Accurate typing of Amyloid proteins is essential for guiding treatment decisions. This gold standard advanced test, powered by Laser Microdissection & Mass Spectrometry allows us to precisely identify amyloid subtypes, helping clinicians provide targeted care. With this launch, we are bringing global standards of Proteomics based diagnostics to patients across India.”
Dr. Lal PathLabs has launched this test, under the guidance of National Amyloidosis Centre, London (UK).
This innovation reaffirms Dr. Lal PathLabs’ commitment to delivering advanced, accessible, and reliable diagnostic services across India.
Corporate Comm India (CCI Newswire)